{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T08:34:31Z","timestamp":1790670871035,"version":"4.1.0"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T00:00:00Z","timestamp":1686096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Abbvie CARO"},{"DOI":"10.13039\/100008467","name":"Canadian Association of Radiation Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008467","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Uro-Oncologic Radiation"},{"DOI":"10.13039\/100009812","name":"Princess Margaret Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009812","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007052","name":"Memorial Sloan Kettering Cancer Center","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100007052","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Grade Group 1 (GG1) prostate cancer should be managed with active surveillance (AS). Global uptake of AS remains disappointingly slow and heterogeneous. Removal of cancer labels has been proposed to reduce GG1 overtreatment. We sought to determine the impact of GG1 disease terminology on individual\u2019s perceptions and decision making.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Discrete choice experiments were conducted on 3 cohorts: healthy men, canonical partners (partners), and patients with GG1 (patients). Participants reported preferences in a series of vignettes with 2 scenarios each, permuting key opinion leader\u2013endorsed descriptors: biopsy (adenocarcinoma, acinar neoplasm, prostatic acinar neoplasm of low malignant potential [PAN-LMP], prostatic acinar neoplasm of uncertain malignant potential), disease (cancer, neoplasm, tumor, growth), management decision (treatment, AS), and recurrence risk (6%, 3%, 1%, &amp;lt;1%). Influence on scenario selection were estimated by conditional logit models and marginal rates of substitution. Two additional validation vignettes with scenarios portraying identical descriptors except the management options were embedded into the discrete choice experiments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Across cohorts (194 healthy men, 159 partners, and 159 patients), noncancer labels PAN-LMP or prostatic acinar neoplasm of uncertain malignant potential and neoplasm, tumor, or growth were favored over adenocarcinoma and cancer (P\u2009&amp;lt;\u2009.01), respectively. Switching adenocarcinoma and cancer labels to PAN-LMP and growth, respectively, increased AS choice by up to 17%: healthy men (15%, 95% confidence interval [CI] = 10% to 20%, from 76% to 91%, P\u2009&amp;lt;\u2009.001), partners (17%, 95% CI = 12% to 24%, from 65% to 82%, P\u2009&amp;lt;\u2009.001), and patients (7%, 95% CI = 4% to 12%, from 75% to 82%, P\u2009=\u2009.063). The main limitation is the theoretical nature of questions perhaps leading to less realistic choices.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\u201cCancer\u201d labels negatively affect perceptions and decision making regarding GG1. Relabeling (ie, avoiding word \u201ccancer\u201d) increases proclivity for AS and would likely improve public health.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jnci\/djad108","type":"journal-article","created":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T21:04:05Z","timestamp":1686171845000},"page":"1364-1373","source":"Crossref","is-referenced-by-count":20,"title":["The influence of the \u201ccancer\u201d label on perceptions and management decisions for low-grade prostate cancer"],"prefix":"10.1093","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1880-6905","authenticated-orcid":false,"given":"Alejandro","family":"Berlin","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, University of Toronto; Radiation Medicine Program, Princess Margaret Cancer Centre; TECHNA Institute, University Health Network , Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Ramotar","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Toronto; Radiation Medicine Program, Princess Margaret Cancer Centre; TECHNA Institute, University Health Network , Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna T","family":"Santiago","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Princess Margaret Cancer Centre; Dalla Lana School of Public Health, University of Toronto , Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihui","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Princess Margaret Cancer Centre; Dalla Lana School of Public Health, University of Toronto , Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"Li","sequence":"additional","affiliation":[{"name":"The University of Western Ontario , London, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Wolinsky","sequence":"additional","affiliation":[{"name":"AnCan Active Surveillance Virtual Support Group; The Active Surveillor Newsletter , Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J D","family":"Wallis","sequence":"additional","affiliation":[{"name":"Division of Urology, Department of Surgery, University of Toronto, Mount Sinai Hospital, and University Hospital Network , Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melvin L K","family":"Chua","sequence":"additional","affiliation":[{"name":"Divisions of Radiation Oncology and Medical Sciences, National Cancer Centre Singapore; Oncology Academic Programme, Duke-NUS Medical School , Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gladell P","family":"Paner","sequence":"additional","affiliation":[{"name":"Departments of Pathology and Surgery, University of Chicago. Chicago , IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodorus","family":"van der Kwast","sequence":"additional","affiliation":[{"name":"Laboratory Medicine Program, University Health Network , Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R","family":"Cooperberg","sequence":"additional","affiliation":[{"name":"Departments of Urology and Epidemiology and Biostatistics, University of California San Francisco Comprehensive Cancer Center , San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J","family":"Vickers","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center , New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R","family":"Urbach","sequence":"additional","affiliation":[{"name":"Institute for Clinical Evaluative Sciences\u00a0(ICES), Department of Surgery, University of Toronto; Perioperative Services, Women\u2019s College Hospital and Research Institute, Toronto , ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott E","family":"Eggener","sequence":"additional","affiliation":[{"name":"Section of Urology, Department of Surgery, The University of Chicago Comprehensive Cancer Center, Chicago , IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,6,7]]},"reference":[{"issue":"7","key":"2023111012331641700_djad108-B1","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/jnci\/djac066","article-title":"Grade migration of prostate cancer in the United States during the last decade","volume":"114","author":"Borregales","year":"2022","journal-title":"J Natl Cancer Inst"},{"issue":"15","key":"2023111012331641700_djad108-B2","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","article-title":"10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer","volume":"375","author":"Hamdy","year":"2016","journal-title":"N Engl J Med."},{"issue":"6","key":"2023111012331641700_djad108-B3","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.eururo.2019.12.017","article-title":"Active surveillance of grade group 1 prostate cancer: long-term outcomes from a large prospective cohort","volume":"77","author":"Tosoian","year":"2020","journal-title":"Eur Urol."},{"issue":"2","key":"2023111012331641700_djad108-B4","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur Urol"},{"issue":"1","key":"2023111012331641700_djad108-B5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/ju.0000000000002757","article-title":"Clinically localized prostate cancer: AUA\/ASTRO guideline, Part I: introduction, risk assessment, staging, and risk-based management","volume":"208","author":"Eastham","year":"2022","journal-title":"J Urol"},{"issue":"2","key":"2023111012331641700_djad108-B6","doi-asserted-by":"publisher","first-page":"134","DOI":"10.6004\/jnccn.2021.0008","article-title":"NCCN guidelines insights: prostate cancer, version 1.2021","volume":"19","author":"Schaeffer","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"suppl 5","key":"2023111012331641700_djad108-B7","doi-asserted-by":"publisher","first-page":"e740","DOI":"10.1097\/JU.0000000000002609.03","article-title":"MP43-03\u2003active surveillance for low-risk prostate cancer: time trends and variation in the AUA QUALITY (AQUA) registry","volume":"207","author":"Cooperberg","year":"2022","journal-title":"J Urol"},{"issue":"19","key":"2023111012331641700_djad108-B8","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1001\/jamainternmed.2013.8405","article-title":"Impact of ductal carcinoma in situ terminology on patient treatment preferences","volume":"173","author":"Omer","year":"2013","journal-title":"JAMA Intern Med"},{"issue":"6","key":"2023111012331641700_djad108-B9","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1001\/jamaoncol.2019.0054","article-title":"The role of disease label in patient perceptions and treatment decisions in the setting of low-risk malignant neoplasms","volume":"5","author":"Dixon","year":"2019","journal-title":"JAMA Oncol"},{"issue":"2","key":"2023111012331641700_djad108-B10","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/j.1539-6924.1988.tb01168.x","article-title":"The social amplification of risk: a conceptual framework","volume":"8","author":"Kasperson","year":"1988","journal-title":"Risk Anal"},{"issue":"6","key":"2023111012331641700_djad108-B11","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1177\/0272989x05282639","article-title":"Cure me even if it kills me: preferences for invasive cancer treatment","volume":"25","author":"Fagerlin","year":"2005","journal-title":"Med Decis Making"},{"issue":"4","key":"2023111012331641700_djad108-B12","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3322\/caac.21283","article-title":"Toward ethically responsible choice architecture in prostate cancer treatment decision-making","volume":"65","author":"Blumenthal-Barby","year":"2015","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"2023111012331641700_djad108-B13","doi-asserted-by":"publisher","first-page":"e234","DOI":"10.1016\/s1470-2045(13)70598-9","article-title":"Addressing overdiagnosis and overtreatment in cancer: a prescription for change","volume":"15","author":"Esserman","year":"2014","journal-title":"Lancet Oncol"},{"issue":"27","key":"2023111012331641700_djad108-B14","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1200\/jco.22.00123","article-title":"Low-grade prostate cancer: time to stop calling it cancer","volume":"40","author":"Eggener","year":"2022","journal-title":"J Clin Oncol"},{"issue":"27","key":"2023111012331641700_djad108-B15","doi-asserted-by":"publisher","first-page":"3106","DOI":"10.1200\/jco.22.00926","article-title":"Renaming Gleason Score 6 prostate to noncancer: a flawed idea scientifically and for patient care","volume":"40","author":"Epstein","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4","key":"2023111012331641700_djad108-B16","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.eururo.2022.09.015","article-title":"Prostate adenocarcinoma grade group 1: rationale for retaining a cancer label in the 2022 World Health Organization classification","volume":"83","author":"Netto","year":"2023","journal-title":"Eur Urol"},{"issue":"6","key":"2023111012331641700_djad108-B17","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1111\/bju.15897","article-title":"Is Gleason 6 cancer? The answer is more than just a \u2018name\u2019","volume":"130","author":"Wilt","year":"2022","journal-title":"BJU Int"},{"key":"2023111012331641700_djad108-B18","doi-asserted-by":"publisher","DOI":"10.1097\/pap.0000000000000400","article-title":"Renaming grade group 1 prostate \u201ccancer\u201d from a pathology perspective: a call for multidisciplinary discussion","author":"Paner","year":"2023","journal-title":"Adv Anat Pathol"},{"issue":"5","key":"2023111012331641700_djad108-B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta5050","article-title":"Eliciting public preferences for healthcare: a systematic review of techniques","volume":"5","author":"Ryan","year":"2001","journal-title":"Health Technol Assess"},{"issue":"2","key":"2023111012331641700_djad108-B20","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s40273-018-0734-2","article-title":"Discrete choice experiments in health economics: past, present and future","volume":"37","author":"Soekhai","year":"2019","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"2023111012331641700_djad108-B21","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1086\/259131","article-title":"A new approach to consumer theory","volume":"74","author":"Lancaster","year":"1966","journal-title":"J Polit Econ"},{"issue":"3","key":"2023111012331641700_djad108-B22","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.reseneeco.2011.02.002","article-title":"Willingness to pay for electric vehicles and their attributes","volume":"33","author":"Hidrue","year":"2011","journal-title":"Resour Energy Econ"},{"issue":"9-10","key":"2023111012331641700_djad108-B23","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1159\/000508755","article-title":"Current role of multiparametric MRI and MRI targeted biopsies for prostate cancer diagnosis in Germany: a Nationwide survey","volume":"104","author":"Saar","year":"2020","journal-title":"Urol Int"},{"issue":"11","key":"2023111012331641700_djad108-B24","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1177\/13591053211037737","article-title":"Multifactorial causal beliefs and colorectal cancer screening: a structural equation modeling investigation","volume":"27","author":"Allen","year":"2022","journal-title":"J Health Psychol"},{"key":"2023111012331641700_djad108-B25","author":"Orme","year":"1998"},{"issue":"10","key":"2023111012331641700_djad108-B26","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1001\/jamaoto.2018.1272","article-title":"Effect of a change in papillary thyroid cancer terminology on anxiety levels and treatment preferences: a randomized crossover trial","volume":"144","author":"Nickel","year":"2018","journal-title":"JAMA Otolaryngol Head Neck Surg."},{"issue":"3","key":"2023111012331641700_djad108-B27","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.eururo.2015.06.046","article-title":"A contemporary prostate cancer grading system: a validated alternative to the Gleason score","volume":"69","author":"Epstein","year":"2016","journal-title":"Eur Urol"},{"issue":"6","key":"2023111012331641700_djad108-B28","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.eururo.2016.05.039","article-title":"Perspectives of prostate cancer patients on Gleason scores and the new grade groups: initial qualitative study","volume":"70","author":"Loeb","year":"2016","journal-title":"Eur Urol"},{"issue":"18","key":"2023111012331641700_djad108-B29","doi-asserted-by":"publisher","first-page":"3354","DOI":"10.1002\/cncr.33621","article-title":"It's all in the name: does nomenclature for indolent prostate cancer impact management and anxiety?","volume":"127","author":"Hudnall","year":"2021","journal-title":"Cancer"},{"issue":"5","key":"2023111012331641700_djad108-B30","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/s0277-9536(99)00145-8","article-title":"Decision-making in the physician-patient encounter: revisiting the shared treatment decision-making model","volume":"49","author":"Charles","year":"1999","journal-title":"Soc Sci Med"},{"issue":"3","key":"2023111012331641700_djad108-B31","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41391-022-00551-4","article-title":"Lifestyle and sociodemographic factors associated with treatment choice of clinically localized prostate cancer in an equal access healthcare system","volume":"25","author":"Anderson","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"6","key":"2023111012331641700_djad108-B32","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1038\/nn.4022","article-title":"Social signals of safety and risk confer utility and have asymmetric effects on observers' choices","volume":"18","author":"Chung","year":"2015","journal-title":"Nat Neurosci"},{"issue":"6","key":"2023111012331641700_djad108-B33","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1080\/23809000.2017.1408412","article-title":"\u2018Shared decision-making, preferences, risk-tolerance, and the cancer patient experience\u2019","volume":"2","author":"LeBlanc","year":"2017","journal-title":"Expert Rev Qual Life Cancer Care"},{"issue":"3","key":"2023111012331641700_djad108-B34","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.eururo.2018.02.026","article-title":"Factors influencing men's choice of and adherence to active surveillance for low-risk prostate cancer: a mixed-method systematic review","volume":"74","author":"Kinsella","year":"2018","journal-title":"Eur Urol"},{"issue":"11","key":"2023111012331641700_djad108-B35","doi-asserted-by":"publisher","first-page":"e14241","DOI":"10.2196\/14241","article-title":"Health-related internet use among men with prostate cancer in Canada: Cancer Registry Survey Study","volume":"21","author":"Bender","year":"2019","journal-title":"J Med Internet Res"},{"issue":"5","key":"2023111012331641700_djad108-B36","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1177\/0033354918791544","article-title":"Health information blocking: responses under the 21st Century Cures Act","volume":"133","author":"Black","year":"2018","journal-title":"Public Health Rep"},{"issue":"1","key":"2023111012331641700_djad108-B37","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1080\/00224545.1977.9923987","article-title":"Primacy versus recency in retention of information and opinion change","volume":"101","author":"Crano","year":"1977","journal-title":"J Soc Psychol"},{"issue":"1","key":"2023111012331641700_djad108-B38","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1600-0560.2011.01848.x","article-title":"The melanoma \u2018epidemic\u2019: lessons from prostate cancer","volume":"39","author":"Glusac","year":"2012","journal-title":"J Cutan Pathol"},{"issue":"2","key":"2023111012331641700_djad108-B39","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1001\/jamainternmed.2013.12738","article-title":"Overdiagnosis in low-dose computed tomography screening for lung cancer","volume":"174","author":"Patz","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"4","key":"2023111012331641700_djad108-B40","doi-asserted-by":"publisher","first-page":"256","DOI":"10.7326\/m15-0970","article-title":"Harms of breast cancer screening: systematic review to update the 2009 U.S. Preventive Services Task Force recommendation","volume":"164","author":"Nelson","year":"2016","journal-title":"Ann Intern Med"},{"issue":"1","key":"2023111012331641700_djad108-B41","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/aln.0000000000002373","article-title":"Why money alone can't (always) \u201cnudge\u201d physicians: the role of behavioral economics in the design of physician incentives","volume":"130","author":"Lubarsky","year":"2019","journal-title":"Anesthesiology"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djad108\/50908209\/djad108.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/115\/11\/1364\/52934484\/djad108.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/115\/11\/1364\/52934484\/djad108.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T07:34:50Z","timestamp":1699601690000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/115\/11\/1364\/7191778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,7]]},"references-count":41,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,6,7]]},"published-print":{"date-parts":[[2023,11,8]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djad108","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11,1]]},"published":{"date-parts":[[2023,6,7]]}}}